ClinicalTrials.gg

Program

HR19042

A development code. Also written as “HR19042 Capsules”, “HR19042 Capsule, Tarpeyo®, Budenofalk®” and “HR19042 capsule”.

Its studies are mostly in Glomerulonephritis, IGA · Hepatitis, Autoimmune, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Aug 17, 20214 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine40 open or runningphase 2since Aug 17, 2021May 13, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2021First study: phase 1 study in Glomerulonephritis, IGAFirst studyNCT04887532 · 12 enrolled · China
  2. Aug 17, 2021Phase 2 study in Glomerulonephritis, IGANCT05016323 · 316 enrolled · China
  3. Jul 25, 2022Phase 2 study in Hepatitis, AutoimmuneNCT05476900 · 69 enrolled · China
  4. Apr 3, 2025Phase 1 study in Glomerulonephritis, IGANCT06922305 · 18 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06922305Glomerulonephritis, IGA · China1CompletedJan 25, 202418
NCT05476900Hepatitis, Autoimmune · China2CompletedMar 14, 202569
NCT05016323Glomerulonephritis, IGA · China2CompletedJun 9, 2024316
NCT04887532Glomerulonephritis, IGA · China1CompletedJul 27, 202112

How it is read

Names in the registry

  • “HR19042 Capsules”, 2 entries
  • “HR19042 Capsule, Tarpeyo®, Budenofalk®”, 1 entry
  • “HR19042 capsule”, 1 entry

Codes read as this program: HR19042.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HR19042 (Jiangsu HengRui Medicine): development program | ClinicalTrials.gg